

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (Previously Presented) A non-catalytic oligonucleotide compound 20_nucleobases in length targeted to a nucleic acid molecule encoding apolipoprotein B, wherein said compound (1) is fully complementary to the nucleotide sequence set forth in SEQ ID NO: 3 excluding the start codon region; (2) comprises a plurality of nucleosides having modified sugar moieties and a plurality of nucleosides having phosphorothioate internucleoside linkages; and (3) demonstrates at least 70% reduction of apolipoprotein B mRNA levels when applied *in vitro* at a concentration of 150nM to HepG2 cells.
- 2-7. (Canceled)
8. (Previously presented) The non-catalytic oligonucleotide compound of claim 1 comprising at least one modified nucleobase.
9. (Previously presented) The non-catalytic oligonucleotide compound of claim 8 wherein the modified nucleobase is a 5-methylcytosine.
10. (Previously presented) The non-catalytic oligonucleotide compound of claim 1 wherein the non-catalytic oligonucleotide compound is a chimeric oligonucleotide.
11. (Canceled)
12. (Previously presented) A composition comprising the non-catalytic oligonucleotide compound of claim 1 and a pharmaceutically acceptable carrier or diluent.
13. (Original) The composition of claim 12 further comprising a colloidal dispersion system.
- 14-19. (Canceled)
20. (Previously presented) The non-catalytic oligonucleotide compound of claim 1, wherein said compound inhibits the expression of the long form of apolipoprotein B, ApoB-100.
- 21-27. (Canceled)
28. (Previously presented) The non-catalytic oligonucleotide compound of claim 1, wherein the compound is a sodium salt.
29. (Previously presented) The non-catalytic oligonucleotide compound of claim 1, wherein the non-catalytic oligonucleotide compound targets a sequence within the range of nucleotides 1 to 103 or 157 to 14121 of SEQ ID NO: 3.

30. (Previously presented) The non-catalytic oligonucleotide compound of claim 1, wherein the oligonucleotide compound targets a sequence within the range of nucleotides 1 to 79 or 182 to 14121 of SEQ ID NO: 3.

31-32. (Canceled)

33. (Previously presented) The non-catalytic oligonucleotide compound of claim 1, wherein the modified sugar moiety is a 2' substituted sugar moiety or a bicyclic sugar moiety.

34. (Previously presented) The non-catalytic oligonucleotide compound of claim 33, wherein the 2' substituted sugar moiety is a 2'-O-methoxyethyl sugar moiety.

35. (Previously presented) The non-catalytic oligonucleotide compound of claim 33, wherein the bicyclic sugar moiety is a locked nucleic acid.

36. (Previously presented) The non-catalytic oligonucleotide compound of claim 1, wherein the oligonucleotide compound is an antisense oligonucleotide.

37-39. (Canceled)